GOSS
What one share of Gossamer Bio holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH
Gossamer Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.21 |
|---|---|
| Profit | −$0.48 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.63 |
| Cash and investments | $0.12 |
| Book value | −$0.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.74 | — | −$0.63 | — | −$0.75 |
| 2018 | — | −$22.59 | $0.54 | −$8.38 | — | −$14.91 |
| 2019 | — | −$3.29 | $0.05 | −$2.70 | — | $5.72 |
| 2020 | — | −$3.55 | $0.02 | −$2.60 | — | $4.34 |
| 2021 | — | −$3.13 | $0.02 | −$2.54 | — | $1.60 |
| 2022 | $0.00 | −$2.71 | $0.00 | −$2.22 | — | $0.13 |
| 2023 | $0.00 | −$1.18 | $0.00 | −$1.04 | — | $0.28 |
| 2024 | $0.51 | −$0.25 | $0.00 | −$0.02 | — | $0.13 |
| 2025 | $0.21 | −$0.75 | $0.00 | −$0.75 | — | −$0.53 |